Aspen Will Slash Prices for Six Cancer Drugs Sold in EU

The European Commission said it has made legally binding an agreement by Aspen Pharma to cut prices for six cancer drugs it markets in Europe by an average of 73 percent.

The six drugs are indicated to treat certain forms of blood cancer, including myeloma and leukemia. According to the commission, Aspen acquired the drugs from another company and then “started in 2012 to progressively increase its prices, often by several hundred percent.”

Aspen said it had entered the agreement despite not agreeing that it had engaged in abusive pricing for the cancer drugs. But the commission said its analysis showed Aspen’s prices exceeded its relevant costs by almost 300 percent on average.